ArticleDiscover oncology2025
Investigating the causal relationship between insomnia and ovarian cancer risk: a Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dissecting the Gut Microbiota-metabolite-coronary Atherosclerosis Axis: Evidence from Two-sample Mendelian Randomization.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe epidemiological association between insomnia and ovarian cancer remains controversial, as observational studies are inherently susceptible to confounding factors and reverse causation bias. While neuroendocrine dysregulation may contribute to the pathogenesis of hormone-sensitive malignancies, there is a paucity of genetic evidence supporting a causal relationship between sleep disturbances and ovarian carcinogenesis.
methodsWe conducted a two-sample Mendelian randomization analysis using summary-level genetic data obtained from separate genome-wide association studies (GWAS) of insomnia and ovarian cancer in European populations. The inverse-variance weighted (IVW) method served as our primary analytical approach, with complementary validation through MR-Egger regression, weighted median estimation, and MR-PRESSO sensitivity analyses. Instrumental variables were stringently selected based on genome-wide significance (P < 5 × 10⁻⁸), linkage disequilibrium thresholds (r² < 0.001), and instrument strength quantification using F-statistics , with all retained SNPs demonstrating strong instrument validity (F > 30). Horizontal pleiotropy was systematically evaluated through Egger intercept testing and MR-PRESSO outlier correction procedures.
resultsThe IVW method found a statistically significant but clinically marginal association between insomnia and ovarian cancer risk (OR = 1.00, 95%CI: 1.00-1.01, p= 0.02). Nonetheless, both the MR-Egger analysis (OR = 1.00, 95%CI: 0.99-1.01, p= 0.68) and the weighted median analysis (OR = 1.00, 95%CI: 0.99-1.01,p= 0.21) produced non-significant results. The instruments are strong (mean F-statistic = 38.8). No evidence of horizontal pleiotropy or heterogeneity was found (MR-PRESSO p= 0.731; Egger intercept p= 0.986; Cochran's Q p= 0.643).
conclusionThe study reveals a modest association between insomnia and ovarian cancer incidence, though this relationship demonstrates limited clinical relevance. Genetic analyses indicate that insomnia does not independently contribute to elevated ovarian cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.